In his articles, Christopher J. Logothetis combines various disciplines, including Oncology and Gastroenterology. He undertakes multidisciplinary studies into Gastroenterology and Urology in his work. In his works, he conducts interdisciplinary research on Urology and Oncology. He incorporates Prostate cancer and Docetaxel in his research. He connects Docetaxel with Cancer in his study. Christopher J. Logothetis performs multidisciplinary study in the fields of Cancer and Cancer research via his papers. Christopher J. Logothetis integrates many fields in his works, including Cancer research and Prostate cancer. As part of his studies on Internal medicine, he frequently links adjacent subjects like Bone remodeling. Christopher J. Logothetis combines topics linked to LNCaP with his work on Prostate.
His study in Androgen receptor extends to Internal medicine with its themes. He integrates Cancer and Regimen in his research. He regularly ties together related areas like Internal medicine in his Regimen studies. He performs multidisciplinary study in Prostate cancer and Prostate in his work. Christopher J. Logothetis integrates Prostate with Prostate cancer in his study. He carries out multidisciplinary research, doing studies in Oncology and Cancer research. He integrates several fields in his works, including Cancer research and Cancer. His work often combines Urology and Dermatology studies. Christopher J. Logothetis performs multidisciplinary study in the fields of Dermatology and Gastroenterology via his papers.
This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.
Abiraterone in Metastatic Prostate Cancer without Previous Chemotherapy
Charles J. Ryan;Matthew R. Smith;Johann S. De Bono;Arturo Molina.
The New England Journal of Medicine (2013)
The Molecular Taxonomy of Primary Prostate Cancer
Adam Abeshouse;Jaeil Ahn;Rehan Akbani;Adrian Ally.
Ipilimumab versus placebo after radiotherapy in patients with metastatic castration-resistant prostate cancer that had progressed after docetaxel chemotherapy (CA184-043): a multicentre, randomised, double-blind, phase 3 trial
Eugene D. Kwon;Charles G. Drake;Howard I. Scher;Karim Fizazi.
Lancet Oncology (2014)
Abiraterone acetate for treatment of metastatic castration-resistant prostate cancer: final overall survival analysis of the COU-AA-301 randomised, double-blind, placebo-controlled phase 3 study
Karim Fizazi;Howard I. Scher;Arturo Molina;Christopher J. Logothetis.
Lancet Oncology (2012)
Trial Design and Objectives for Castration-Resistant Prostate Cancer: Updated Recommendations From the Prostate Cancer Clinical Trials Working Group 3
Howard I. Scher;Michael J. Morris;Walter M. Stadler;Celestia Higano.
Journal of Clinical Oncology (2016)
Abiraterone acetate plus prednisone versus placebo plus prednisone in chemotherapy-naive men with metastatic castration-resistant prostate cancer (COU-AA-302): final overall survival analysis of a randomised, double-blind, placebo-controlled phase 3 study
Charles J. Ryan;Matthew R. Smith;Karim Fizazi;Fred Saad.
Lancet Oncology (2015)
Steps toward mapping the human vasculature by phage display
Wadih Arap;Mikhail G. Kolonin;Martin Trepel;Johanna Lahdenranta.
Nature Medicine (2002)
A prospective randomized trial comparing MVAC and CISCA chemotherapy for patients with metastatic urothelial tumors.
Christopher J. Logothetis;Francisco H. Dexeus;Laury Finn;Avishay Sella.
Journal of Clinical Oncology (1990)
Randomized, Double-Blind, Phase III Trial of Ipilimumab Versus Placebo in Asymptomatic or Minimally Symptomatic Patients With Metastatic Chemotherapy-Naive Castration-Resistant Prostate Cancer
Tomasz M. Beer;Eugene D. Kwon;Charles G. Drake;Karim Fizazi.
Journal of Clinical Oncology (2017)
Genomic and Functional Approaches to Understanding Cancer Aneuploidy
Alison M. Taylor;Alison M. Taylor;Juliann Shih;Gavin Ha;Gavin Ha;Galen F. Gao.
Cancer Cell (2018)
If you think any of the details on this page are incorrect, let us know.
We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below: